Black Diamond Therapeutics, Inc. (BDTX) — 10-Q Filings
All 10-Q filings from Black Diamond Therapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
BDTX Swings to Profit on $70M License Revenue, R&D Costs Down
— Nov 6, 2025 Risk: medium
Black Diamond Therapeutics, Inc. (BDTX) reported a significant financial turnaround for the nine months ended September 30, 2025, achieving a net income of $37, -
BDTX Losses Widen Amid Increased R&D Spend, Cash Burn Continues
— Aug 7, 2025 Risk: high
Black Diamond Therapeutics, Inc. (BDTX) reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The comp -
Black Diamond Therapeutics Files Q1 2025 10-Q
— May 12, 2025 Risk: medium
Black Diamond Therapeutics, Inc. filed its Q1 2025 10-Q on May 12, 2025, reporting financial results for the period ending March 31, 2025. The company, formerly -
Black Diamond Therapeutics Files Q3 2024 10-Q
— Nov 5, 2024 Risk: medium
Black Diamond Therapeutics, Inc. filed its Q3 2024 10-Q report on November 5, 2024, covering the period ending September 30, 2024. The company, formerly Aset Th -
Black Diamond Therapeutics Files Q2 2024 10-Q
— Aug 6, 2024 Risk: medium
Black Diamond Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly Aset Therapeutics, Inc., is focused on biological pro -
Black Diamond Therapeutics, Inc. Files Q1 2024 10-Q Report
— May 9, 2024 Risk: medium
Black Diamond Therapeutics, Inc. (BDTX) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Black Diamond Therapeutics, Inc. filed its quarterly report
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX